Istradefylline-Inhibitors-DateSheet

Product Name:

Istradefylline CAS No.:

155270-99-8Product Data Sheet

Cat. No.:

HY-10888MWt:

384.43Formula:

C20H24N4O4Purity :

>98%

Solubility:Mechanisms:

Biological Activity:

Pathways:GPCR/G protein; Target:Adenosine Receptor DMSO

g y Istradefylline(KW6002) is a very potent, selective and orally active adenosine A2A receptor

antagonist(Ki=2.2 nM) in experimental models of Parkinson's disease.

IC50 value: 2.2 nM (Ki)

Target: adenosine A2A receptor Istradefylline reduces dyskinesia resulting from long-term treatment with classical antiparkinson drugs such as levodopa. Istradefylline is an analog of caffeine.

References:

[1]. Park A, Stacy M.

Istradefylline for the treatment of Parkinson's disease.

Expert Opin Pharmacother. 2012 Jan;13(1):111-4.

[2]. Knebel W, et al. Population Pharmacokinetic-Pharmacodynamic Analysis of Istradefylline in Patients With Parkinson

Disease.

J Clin Pharmacol. 2011 Dec 12.

[3]. Pourcher E,et al. Istradefylline for Parkinson's disease patients experiencing motor fluctuations: results of the KW-

6002-US-018 study.

Parkinsonism Relat Disord. 2012 Feb;18(2):178-84.[4]R N Caution: Not fully tested. For research purposes only

Medchemexpress LLC [4]. Rao N.

.Re: Efflux transporter-mediated interactions with atorvastatin--interesting findings with multiple